$CTIX Recent Headlines

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$CTIX Recent Headlines







Cellceutix jumps on QIDP tag

23 min ago1:23 p.m. Dec. 8, 2014
- Seeking Alpha





Cellceutix Brilacidin IND effective, Phase 2 to begin

9:31 a.m. Oct. 13, 2014
- Seeking Alpha





Regulatory Support Creates Opportunity For Antibiotic Makers Otonomy And Cellceutix

9:02 a.m. Sept. 25, 2014
- Seeking Alpha





Update: Cellceutix Calls Out To President Obama About Brilacidin

2:38 p.m. Sept. 21, 2014
- Seeking Alpha




10-K: CELLCEUTIX CORP
12:53 p.m. Sept. 15, 2014
- Edgar Online - (EDG = 10Q, 10K)





Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol

2:06 a.m. Sept. 14, 2014
- Seeking Alpha





The Antibiotic Resistance Triple Threat

1:05 p.m. Sept. 4, 2014
- Seeking Alpha





Cellceutix completes enrollment in Brilacidin trial

8:45 a.m. Aug. 19, 2014
- Seeking Alpha





Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market?

10:38 a.m. Aug. 14, 2014
- Seeking Alpha




10-Q: CELLCEUTIX CORP
9:15 a.m. May 12, 2014
- Edgar Online - (EDG = 10Q, 10K)





Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix

9:34 a.m. April 25, 2014
- Seeking Alpha




10-Q: CELLCEUTIX CORP
4:09 p.m. Feb. 10, 2014
- Edgar Online - (EDG = 10Q, 10K)





Cellceutix Is Significantly Undervalued Considering The Value Of Brilacidin

9:31 a.m. Jan. 28, 2014
- Seeking Alpha





Cellceutix Corp.: A Biotech With High Risk But High Reward

3:17 p.m. Jan. 2, 2014
- Wall St. Cheat Sheet





Cellceutix: An Undiscovered Company Set To Rise In 2014

9:06 a.m. Dec. 16, 2013
- Seeking Alpha





3 Innovative Biotech Companies Poised To Shine At TAP Partnership Conference

5:38 a.m. Nov. 19, 2013
- Seeking Alpha




10-Q: CELLCEUTIX CORP
5:06 p.m. Nov. 8, 2013
- Edgar Online - (EDG = 10Q, 10K)




10-K: CELLCEUTIX CORP
3:01 p.m. Sept. 30, 2013
- Edgar Online - (EDG = 10Q, 10K)




10-Q: CELLCEUTIX CORP
1:18 p.m. May 20, 2013
- Edgar Online - (EDG = 10Q, 10K)





Interview with CEO of Cellceutix Corporation: Leo Ehrlich

8:57 a.m. Nov. 15, 2011
- GuruFocus.com










Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA
7:01 a.m. Today7:01 a.m. Dec. 8, 2014
- Marketwired




Cellceutix: December to Be Momentous Month in Company's History
7:02 a.m. Nov. 24, 2014
- Marketwired




These Medical Stocks Are Reaching A Fever Pitch Following Midterm Elections
9:54 a.m. Nov. 12, 2014
- ACCESSWIRE




Patient Enrollment in Cellceutix Phase 2 Clinical Trial of
Brilacidin-OM for Oral Mucositis Targeted to Begin in December 2014
7:01 a.m. Nov. 11, 2014
- Marketwired




Cellceutix's New Chief Operating Officer Dr. James Alexander
Addresses Shareholders
6:00 a.m. Oct. 31, 2014
- Marketwired




Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI
Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
10:52 a.m. Oct. 23, 2014
- Marketwired




Cellceutix Investigational New Drug (IND) Application Becomes
Effective, Selects First Site for Phase 2 Clinical Trial of New
Treatment for Oral Mucositis
8:02 a.m. Oct. 13, 2014
- Marketwired




Cellceutix Provides Update to Shareholders
11:30 a.m. Sept. 24, 2014
- Marketwire




Cellceutix to President Obama: We Have the Tools and Will Rise Up to
the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a
Serious Threat to Public Health
6:15 a.m. Sept. 19, 2014
- Marketwire




Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b
Trial; Company Submits Investigational New Drug Application to FDA
for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
2:01 p.m. Sept. 9, 2014
- Marketwire




Cellceutix to Present at Rodman & Renshaw's 16th Annual Global
Investment Conference
10:17 a.m. Sept. 5, 2014
- Marketwire




Cellceutix Appoints Dr. Barry Schechter to Board of Directors as
Company Focuses on Meeting Requirements for Stock Exchange Uplisting
6:01 a.m. Sept. 2, 2014
- Marketwire




Cellceutix Completes Enrollment in Phase 2b Clinical Trial of
Brilacidin for Acute Bacterial Skin and Skin Structure Infections
(ABSSSI)
7:31 a.m. Aug. 19, 2014
- Marketwire




Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for
Oral Mucositis
6:01 a.m. Aug. 11, 2014
- Marketwire




Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of
Clinical Trial
5:04 a.m. Aug. 8, 2014
- Marketwire




Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling
Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial
for Acute Bacterial Skin and Skin Structure Infections Expected This
Month
6:01 a.m. Aug. 4, 2014
- Marketwire




Cellceutix Announces Breakthrough in the Formulation of Its Novel
Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot
Ulcers
6:01 a.m. July 14, 2014
- Marketwire




Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data
Safety Monitoring Board; Best Possible Outcome, No Treatment-Related
Serious Adverse Events (SAEs)
6:00 a.m. July 7, 2014
- Marketwire




Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant
6:01 a.m. June 23, 2014
- Marketwire




Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering
Eighth Cohort
6:01 a.m. June 16, 2014
- Marketwire




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dotwork's AI Leap: Acquires Arcario to Revolutionize Strategy

Updated Category News Views 108

Transformations in enterprise management are knocking at the door with Dotwork's latest move. Their strategic acquisition of Arcario Group aims to flip the lid on how companies tie strategies to their daily grind using AI. Let me level with you—this ain't about just spicing up some dashboards or workflows. We're talking about an enterprise-level overhaul in the very way...

Continue Reading
EQT's Strategic Moves in Q3 2026 Amid Strong Execution

Updated Category News Views 111

Inside EQT's Third Quarter Performance EQT Corporation has rolled out its third quarter 2026 results, and boy, they’ve been playing their cards with some finesse. The company's sporting a strong showing despite the tricky currents in the natural gas market where prices took a nosedive. What's keeping EQT upright, you ask? It's their smart marketing maneuvers and a...

Continue Reading
Small Biz Financing Soars Amid Credit Struggles

Updated Category News Views 32

Record Financing Applications, But Not All is Rosy Diving headlong into this 1West data is like clutching at a double-edged sword. On one side, we've got record-breaking numbers—48,975 financing applications in Q3 alone. That’s a staggering 25% hike over last year. But before you pop the champagne, let's pivot to the other edge: dwindling financial health. With the...

Continue Reading
Scania's Q3 Results: A Resilient Yet Uneven Ride

Updated Category News Views 71

Scania Steadies the Ship in Q3 with Robust Growth Sailing through a patchy global market, Swedish powerhouse Scania's latest quarterly figures reflect a mixed bag of results. Their performance in this third quarter of 2026 stood strong, despite some wobbles. The company showed resilience in sales and profitability, with numbers telling a tale that's a bit like a truck...

Continue Reading
Probiotics in Animal Feed: Market Reaches $8.76B by 2031

Updated Category News Views 0

Let's cut straight to the chase: the probiotics in animal feed market is steaming ahead, set to grow from a respectable $5.82 billion in 2026 to a hearty $8.76 billion by 2031. We're talking about a solid CAGR of 8.5% here. Now that's the kind of growth trajectory that gets even the most jaded traders sitting up and taking notice. Big Numbers in Livestock Nutrition...

Continue Reading
Burns Harbor Bags $11.2M to Turbocharge Operations

Updated Category News Views 120

Funding Boon for Burns Harbor It’s not every day you see a steady hand of federal money pouring into a port like Burns Harbor, and there’s an $11.2 million cherry on top from Uncle Sam to modernize this place. Yeah, you heard right—a cool eleven million to spruce up Indiana’s port operations, aimed straight at making Burns Harbor more nimble on the international...

Continue Reading
Hengrui Pharma: Innovating Oncology on Global Stage

Updated Category News Views 73

Setting the Global Stage for Chinese Pharmaceutical Innovation Ah, China is no longer just the factory of the world; it's rolling its sleeves up and getting deep into the pharma game. Hengrui Pharma, a heavyweight in China's pharmaceutical scene, just pulled off a commendable performance at the European Society for Medical Oncology (ESMO) Congress 2026 over in Madrid....

Continue Reading
Multiplier's Data Signals Global Hiring Evolution

Updated Category News Views 23

Shaking Up the Global Hiring Playbook You think you know how hiring works globally? Think again. Based on data from a whopping 38,000 cross-border hires, Multiplier's latest Talent Trends has spilled some hot new beans on how companies are rethinking their talent acquisition strategies. This isn’t just some thumb-twiddling speculation either—it’s grounded in real...

Continue Reading
isinwheel Rolls Out Black Friday Bonanza with Deals

Updated Category News Views 9

Deals That Roll — The isinwheel Advantage Black Friday isn't just about doorbuster deals on oversized TVs anymore, folks. This year, isinwheel is revving it up with a buffet of e-mobility deals that, quite frankly, shouldn't be ignored. From lightweight scooters for swift metro dashes to beefier rides for off-road escapades, they're wheeling out a host of offerings...

Continue Reading
Seasonal Hiring Booms as Firms Eye Long-Term Talent

Updated Category News Views 70

A Strategic Shift in Seasonal Hiring It ain't just about the holiday rush anymore, folks. Companies are waking up to the idea that seasonal gigs are more than a temporary Band-Aid. This year, nearly 2 out of 5 companies are planning to bring more seasonal folks into the fold compared to last year. That means a good dose of them are looking for longer-term value—like...

Continue Reading

Top 5 Most Recently Viewed Articles

BioCardia's Innovative Therapy Shows Promise in Cardiac Care

Updated Category News Views 201

BioCardia Unveils Promising Results in CardiAMP Cell Therapy BioCardia, Inc. (NASDAQ: BCDA), a pioneer in cell therapy for cardiovascular conditions, recently shared the groundbreaking results from its CardiAMP trial. This innovative cellular therapy targets chronic myocardial ischemia, a serious health issue impacting many individuals due to reduced blood flow to the...

Continue Reading
Exploring Smart Elevators: A Future of Safe and Efficient Movement

Updated Category News Views 139

Understanding the Smart Elevator Market Growth The Smart Elevator Market is rapidly evolving, driven by urbanization, energy efficiency needs, and a focus on safety. As construction of modern residential and commercial buildings continues to rise, smart elevators are becoming essential components of a contemporary infrastructure. These advancements not only enhance...

Continue Reading
Krispy Krunchy Chicken® Marks Unprecedented Growth in 2024

Updated Category News Views 317

Krispy Krunchy Chicken® Shares Successes of 2024 Krispy Krunchy Chicken, a leading player in the fast-food industry, has achieved remarkable success in 2024, closing the year with over 605 new store openings. With a vision focused on innovation and expansion, Krispy Krunchy continues to redefine the hot food concept within convenience stores. Their rapid growth reflects...

Continue Reading
Dofo Tea's Redesign Brings Tradition to Modern Life

Updated Category News Views 13

A Fresh Approach to Ancient Tea Rituals It's about time someone pulled back the velvet curtain on Chinese tea rituals for the rest of us. Dofo Tea, hailing from Chaozhou and steeped in the illustrious Teochew Gongfu Tea tradition, just gave itself a makeover. And it's not your typical slap-a-new-label-on-it kind of refresh. Instead, they've ripped open the seams of...

Continue Reading
Micron Technology's Recovery: Investing in Tomorrow's Chips

Updated Category News Views 228

Shares of Micron Technology (NASDAQ: MU) surged impressively after the company’s fiscal results showed a 93% revenue jump to $7.8 billion. This spike came despite skepticism from Wall Street analysts who had lowered price targets ahead of the earnings announcement; yet, those same analysts rushed to revise targets upwards after witnessing Micron’s performance. With...

Continue Reading